[Kathrine]

The trial in which I am involved is still in its very early stages of planning and will take place in a country and at sites that have not previously had any multinational HIV prevention trials.  From my perspective there is extremely limited knowledge about GPP across the whole research team, including the sponsor, the protocol development team, sites investigators being vetted for participation, regulatory bodies, not to speak of community stakeholders.   One very concrete learning from Lesson 1 is the idea that the sponsor should adopt the GPP guidelines as a requirement — this will be a goal which should be achievable with sufficient explanation about GPP and the ways in which they function to strengthen the overall trial design and implementation.  It is very encouraging to read that in other sites the whole research team is knowledgeable about and invested in GPP and gives me hope that we will get there as well.